Q4 2025 Uniqure NV Earnings Call Transcript

Mar 2, 2026 / 01:00 PM GMT

Release Date Price: $10.42 (-34.08%)

Transcript 10-K8-K

Key Points

Positve

uniQure NV (QURE) reported groundbreaking 3-year data from their phase 12 study of AMT 130, showing significant slowing of Huntington's disease progression.
The company has successfully developed two approved gene therapies, demonstrating their capability in the gene therapy space.
uniQure NV (QURE) has a strong balance sheet with cash and investment securities totaling $622.5 million, providing financial stability.
The company is actively engaging with regulatory authorities outside the US, indicating potential for international expansion.
uniQure NV (QURE) is committed to advancing AMT 130 and other programs responsibly and expeditiously, showing dedication to their pipeline.

Negative

The FDA has recommended a phase 3 randomized double-blind sham surgery controlled study for AMT 130, which could delay the approval process.
Revenue for 2025 decreased to $16.1 million from $27.1 million in 2024, indicating a decline in financial performance.
The company faces challenges in demonstrating treatment effects in early Huntington's disease patients due to slow disease progression.
There are concerns about the feasibility and ethical implications of conducting a multi-year sham controlled study for AMT 130.
uniQure NV (QURE) experienced a $12.8 million increase in selling, general, and administrative expenses, impacting their financials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

QURE.OQ - Uniqure NV
Q4 2025 Uniqure NV Earnings Call
Mar 02, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by. My name is Kate, and I'll be your conference operator today. At this time, I would like to welcome everyone to the unicure fourth quarter and year end 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star, followed with the number 1 on your telephone keypad. If you would like to withdraw your question, press one again.

Thank you. I would now like to turn the call over to Kara Russo, senior director of investor relations. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.